Precision BioSciences
Utility Patents

Last updated:

List of all Precision BioSciences patents 18 in total

Status Patent
Grant
Utility: Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) External link
Filling date: 7 Nov 2025 Issue date: 12 Jul 2022
Grant
Utility: Co-stimulatory domains for use in genetically-modified cells External link
Filling date: 7 Nov 2025 Issue date: 29 Mar 2022
Grant
Utility: Engineered nucleases useful for treatment of hemophilia A External link
Filling date: 7 Nov 2025 Issue date: 22 Mar 2022
Grant
Utility: Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome External link
Filling date: 7 Nov 2025 Issue date: 15 Mar 2022
Grant
Utility: Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene External link
Filling date: 7 Nov 2025 Issue date: 8 Mar 2022
Grant
Utility: Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene External link
Filling date: 7 Nov 2025 Issue date: 8 Mar 2022
Grant
Utility: Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) External link
Filling date: 7 Nov 2025 Issue date: 30 Nov 2021
Grant
Utility: Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome External link
Filling date: 7 Nov 2025 Issue date: 12 Oct 2021
Grant
Utility: Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene External link
Filling date: 7 Nov 2025 Issue date: 6 Jul 2021
Grant
Utility: Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR) External link
Filling date: 7 Nov 2025 Issue date: 18 May 2021
Grant
Utility: Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome External link
Filling date: 7 Nov 2025 Issue date: 1 Dec 2020
Grant
Utility: Co-stimulatory domains for use in genetically-modified cells External link
Filling date: 7 Nov 2025 Issue date: 13 Oct 2020
Grant
Utility: Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene External link
Filling date: 7 Nov 2025 Issue date: 13 Oct 2020
Grant
Utility: Treatment of retinitis pigmentosa using engineered meganucleases External link
Filling date: 7 Nov 2025 Issue date: 1 Sep 2020
Grant
Utility: Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof External link
Filling date: 7 Nov 2025 Issue date: 18 Aug 2020
Grant
Utility: Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome External link
Filling date: 7 Nov 2025 Issue date: 26 May 2020
Grant
Utility: Self-limiting viral vectors encoding nucleases External link
Filling date: 7 Nov 2025 Issue date: 26 May 2020
Grant
Utility: Treatment of retinitis pigmentosa using engineered meganucleases External link
Filling date: 7 Nov 2025 Issue date: 31 Mar 2020

Showing 1 to 18 of 18 patents.